Brainstorm Cell Therapeutics provided an update on the grant and allowance of three patent applications for NurOwn and NurOwn-Exosomes. The European Patent office granted patent No. 3105587 titled ‘Method of Qualifying of Cells’ for a method of qualifying whether a cell population is a suitable therapeutic for treating ALS. The patent also grants claims for an isolated population of mesenchymal stem cells for use in treating ALS. The Australian patent Office granted patent No. 2019252987 titled ‘Cell-Type Specific Exosomes and Use Thereof’ for an isolated Exosomes population derived from MSC-NTF cells as well as a pharmaceutical composition for the treatment of neurodegenerative diseases. The Israel Patent Office announced the allowance of the same claims for application No. 277447 with an Acceptance date on December 01, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCLI:
- BrainStorm CEO issues letter to shareholders
- BrainStorm reports ‘productive’ meeting with FDA to discuss NurOwn
- Biotech Alert: Searches spiking for these stocks today
- Brainstorm Cell Therapeutics (NASDAQ:BCLI) to Meet with FDA for New Treatment Plans
- BrainStorm granted in-person meeting with the FDA for Phase 3 ALS trial
